ライフサイエンスコーパス: methotrexate

1 herapeutic drugs (vincristine, etoposide and methotrexate).

2 and methotrexate; and 386 had adalimumab and methotrexate).

3 30 mg (p<0.0001 for both doses vs continued methotrexate).

4 30 mg (p<0.0001 for both doses vs continued methotrexate).

5 , 2016, 224 controls received tacrolimus and methotrexate.

6 ients with a previous inadequate response to methotrexate.

7 eceived GVHD prophylaxis with tacrolimus and methotrexate.

8 69 (44%) of 386 patients with adalimumab and methotrexate.

9 l recovery after exposure to camptothecin or methotrexate.

10 y months, yet all of them went on to require methotrexate.

11 t decades with the introduction of high-dose methotrexate.

12 ted uveitis who were taking a stable dose of methotrexate.

13 y with glucocorticosteroids, thiopurines, or methotrexate.

14 gs: etanercept, ustekinumab, adalimumab, and methotrexate.

15 h tumor necrosis factor inhibitors than with methotrexate.

16 week 16, comparing adalimumab 0.8 mg/kg with methotrexate.

17 achieved clear or minimal PGA compared with methotrexate.

18 or in combination with either ciclosporin or methotrexate.

19 favoured the combination of prednisone plus methotrexate.

20 the MAP group: bone marrow infarction due to methotrexate.

21 rDHFR-1 exhibited similar affinities towards methotrexate.

22 and not to original treatment with high-dose methotrexate.

23 tabolism revealed the mechanism of action of methotrexate.

24 y diseases, sulfasalazine and the antifolate methotrexate.

25 xate in patients with inadequate response to methotrexate.

26 p=0.06 for tocilizumab plus methotrexate vs methotrexate, 1.14, 1.01-1.29, p=0.0356 for tocilizumab

27 Prior treatment included methotrexate (100%) and actinomycin D (7%).

28 reported in 102 patients (47%) on continued methotrexate, 103 (47%) on upadacitinib 15 mg, and 105 (

29 Of 270 children taking methotrexate, 130 (48.1%) reported 1 or more AEs associa

30 hosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of

31 , oral prednisolone >10 mg/day, thiopurines, methotrexate); (2) anti-tumor necrosis factor agents; (3

32 Patients were randomized to receive oral methotrexate, 25 mg weekly (n = 107), or oral mycophenol

33 r panuveitis were randomized to receive oral methotrexate, 25 mg weekly, or oral mycophenolate mofeti

34 of R-MBVP (rituximab 375 mg/m(2) day (D) 1, methotrexate 3 g/m(2) D1; D15, VP16 100 mg/m(2) D2, BCNU

35 randomly assigned to receive four courses of methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2

36 plantation, dactinomycin (3.8, 1.3-11.3) and methotrexate (3.3, 1.0-10.2); for lung transplantation,

37 ignificant, 5 patients were still treated by methotrexate, 3 by TNF-blockers, highlighting long-term

38 ts developed a serious treatment-related AE (methotrexate, 3; fumaric acid esters, 2; and adalimumab,

39 mbining vinblastine (5 mg/m(2) per dose) and methotrexate (30 mg/m(2) per dose), administered weekly

40 k 16 was achieved by 19 of 60 patients given methotrexate (31.7%) and 10 of 51 patients given placebo

41 (n=240) or investigator's choice (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docet

42 Cyclosporine (66.4%), methotrexate (47.3%), azathioprine (30.9%), and anti-TNF

43 6 3-week cycles, or physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 30

44 nib monotherapy versus either adalimumab and methotrexate (-6 [-14 to 3]) or tofacitinib and methotre

45 otrexate (MTX) and its metabolites 7-hydroxy methotrexate (7-OH MTX) and 2,4-diamino-N(10)-methylpter

46 hotrexate (-6 [-14 to 3]) or tofacitinib and methotrexate (-8 [-16 to 1]).

47 A single, systemic dose of methotrexate, a DNA-synthesis (S phase) inhibitor, has b

48 Methotrexate, a pillar in the treatment of cancer since

49 reatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced

50 SKK 2000 regimen excluding intraventricular methotrexate, aiming to achieve similar outcome (2-year

51 ectiveness is not demonstrated compared with methotrexate alone in the United Kingdom setting.

52 39 316, with a 0.30 QALY gain compared with methotrexate alone, resulting in an incremental cost-eff

53 Compared with methotrexate alone, the addition of anti-TNF drugs was s

54 ress through MTHFD1L knockdown or the use of methotrexate, an antifolate drug, sensitizes cancer cell

55 Twenty-seven patients were randomized to methotrexate and 16 to mycophenolate mofetil; 30 had acu

56 atients who received certolizumab pegol plus methotrexate and 386 [74%] of 523 patients who received

57 aric acid esters, 2; and adalimumab, 1), but methotrexate and biologic agents were taken for a mean d

58 rspective, an initial strategy of etanercept-methotrexate and biologics with similar cost and efficac

59 The treatment allowed dosing adjustments of methotrexate and capecitabine for pretreatment renal fun

60 t the CRP/IL-6/IL-1 axis, including low-dose methotrexate and colchicine, are being explored.

61 es 1, 3, 5, and 7 alternating with high-dose methotrexate and cytarabine on courses 2, 4, 6, and 8.

62 d among eight patients who were treated with methotrexate and eight untreated age-matched control sub

63 orubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine plus a tyrosine ki

64 d female with psoriatic arthritis, receiving methotrexate and infliximab.

65 100 mg/m(2) on days 1 to 5, and a regimen of methotrexate and mercaptopurine.

66 Methotrexate and mycophenolate mofetil are commonly used

67 ing intracellular folate metabolism, such as methotrexate and pemetrexed.

68 rypanosoma brucei exposed to the antifolates methotrexate and raltitrexed.

69 The use of methotrexate and subsequently biologic therapies (such a

70 The ICERs for first-line etanercept-methotrexate and triple therapy were $2.7 million per QA

71 59-2.51 for tocilizumab plus methotrexate vs methotrexate, and 1.86, 1.48-2.32 for tocilizumab vs met

72 3 (46%) of 376 patients with tofacitinib and methotrexate, and 169 (44%) of 386 patients with adalimu

73 ) of 376 patients receiving tofacitinib plus methotrexate, and 36 (9%) of 386 patients receiving adal

74 orticosteroids, vincristine, L-asparaginase, methotrexate, and 6-mercaptopurine.

75 of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the t

76 xceed 1 g from day 5 to day 35); tacrolimus, methotrexate, and bortezomib (bortezomib 1.3 mg/m(2) int

77 de, 0.98 (0.76-1.27; p=0.92) for tacrolimus, methotrexate, and bortezomib, and 1.10 (0.86-1.41; p=0.4

78 d to the three study arms: 89 to tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotre

79 68 (76%) had grade 4 events with tacrolimus, methotrexate, and bortezomib; and 18 (20%) had grade 3 a

80 n cyclophosphamide; 73 [82%] for tacrolimus, methotrexate, and bortezomib; and 78 [85%] for tacrolimu

81 oral metronomic chemotherapy with erlotinib, methotrexate, and celecoxib is efficacious in platinum-r

82 k cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m(2) cycloph

83 ysician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and d

84 therapies (ie, intravenous cyclophosphamide, methotrexate, and infliximab) in these patients may be a

85 days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc 300 mg orally twi

86 and bortezomib; and 78 [85%] for tacrolimus, methotrexate, and maraviroc) and cardiac (43 [47%], 44 [

87 and 1.10 (0.86-1.41; p=0.49) for tacrolimus, methotrexate, and maraviroc.

88 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc.

89 hotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycopheno

90 nd maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine.

91 included calcineurin inhibitor, short-course methotrexate, and methylprednisolone.

92 1.14, 1.01-1.29, p=0.0356 for tocilizumab vs methotrexate, and p=0.59 for tocilizumab plus methotrexa

93 therapy with 6-mercaptopurine, vincristine, methotrexate, and prednisone (POMP), with four intensifi

94 a by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy.

95 point of phase I was to determine the OBD of methotrexate, and that of phase II was to determine the

96 nd salicylic acid along with oral retinoids, methotrexate, and tumor necrosis factor inhibitors as mo

97 citinib monotherapy; 376 had tofacitinib and methotrexate; and 386 had adalimumab and methotrexate).

98 ents: self-injectable biologics, infliximab, methotrexate, apremilast, and phototherapy.

99 proliferative and pro-respiratory effects of methotrexate are AMPK-dependent, as cells with reduced A

100 ive conditioning, unrelated donor (URD), and methotrexate are not known.

101 athioprine, mercaptopurine, thioguanine) and methotrexate are widely used in a variety of clinical ma

102 tocilizumab arm, and 48 (44%) of 108 in the methotrexate arm (relative risk [RR] 2.00, 95% CI 1.59-2

103 tocilizumab arm, and 83 (77%) of 108 in the methotrexate arm achieved sustained remission (RR 1.13,

104 86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained remission on the ini

105 , 103 to the tocilizumab arm, and 108 to the methotrexate arm).

106 ts to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to

107 86%) of 106 patients in the tocilizumab plus methotrexate arm, 91 (88%) of 103 in the tocilizumab arm

108 e use of mycophenolate mofetil compared with methotrexate as first-line corticosteroid-sparing treatm

109 within-trial analysis found that etanercept-methotrexate as first-line therapy provided marginally m

110 ays -3, -2, -1 in addition to tacrolimus and methotrexate as GVHD prophylaxis.

111 This screen identified methotrexate as the most potent small molecule drug, amo

112 Methotrexate-associated hepatic transaminase elevations

113 ous adalimumab (40 mg every other week) plus methotrexate at 194 centres in 25 countries.

114 cs were efficacious compared with placebo or methotrexate at 3-4 months.

115 ronic data capture system, to receive either methotrexate at a starting dose of 17.5 mg/week or place

116 permuted-block schedule stratified by use of methotrexate at baseline (0, >0 to <12.5 mg/week, or >/=

117 al, but who were treated with tacrolimus and methotrexate at centres not participating in the trial.

118 onotherapy of of upadacitinib or to continue methotrexate at their existing dose as blinded study dru

119 a randomized, double-blind trial of low-dose methotrexate (at a target dose of 15 to 20 mg weekly) or

120 e as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 7

121 apy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy.

122 confirmed PCNSL after experiencing high-dose methotrexate-based chemotherapy failure who were not eli

123 High-dose methotrexate-based chemotherapy is standard for primary

124 lymphoma (PCNSL) are treated with high-dose methotrexate-based chemotherapy, which requires hospital

125 Induction consists of high-dose methotrexate-based polychemotherapy for most patients, w

126 harmacology paradigm, wherein the same drug (methotrexate) binds to multiple non-homologous RLM drug

127 We show here that methotrexate blocked Wnt-induced endocytic lysosomal act

128 KCl or methotrexate can be injected directly into the foetal po

129 stablished drugs such as glucocorticoids and methotrexate can reduce OA pain.

130 These findings indicate that methotrexate chemotherapy exposure is associated with pe

131 Developing a mouse model of methotrexate chemotherapy-induced neurological dysfuncti

132 microstructure, and cognitive behavior after methotrexate chemotherapy.

133 n therapy was non-inferior to adalimumab and methotrexate combination therapy in the treatment of rhe

134 INTERPRETATION: Tofacitinib and methotrexate combination therapy was non-inferior to ada

135 Understanding the mechanism of action of methotrexate could be instructive in the appropriate use

136 r biologic therapies, including thiopurines, methotrexate, cyclosporine, tacrolimus, TNF-alpha antago

137 e first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (calle

138 pared with 23% (14-31) of those treated with methotrexate-cytarabine alone (hazard ratio 0.46, 95% CI

139 -0.74) and 30% (21-42) of those treated with methotrexate-cytarabine plus rituximab (0.61, 0.40-0.94)

140 m(2) on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiot

141 tients with stable atherosclerosis, low-dose methotrexate did not reduce levels of interleukin-1beta,

142 Methotrexate did not result in lower interleukin-1beta,

143 Therapy with systemic methotrexate did not suffice, as all the patients also r

144 tinib and methotrexate versus adalimumab and methotrexate (difference 2% [98.34% CI -6 to 11]) but no

145 %) of 386 patients receiving adalimumab plus methotrexate discontinued due to adverse events.

146 r investigator's choice of standard doses of methotrexate, docetaxel, or cetuximab intravenously (sta

147 cluding fluorouracil, carmustine, cisplatin, methotrexate, doxorubicin and paclitaxel.

148 therapy disposition, including drugs such as methotrexate, doxorubicin, paclitaxel, docetaxel, irinot

149 armacological inhibition of folate action by methotrexate during neurulation induces NTDs by inhibiti

150 nted into the microenvironment of previously methotrexate-exposed brains, indicating an underlying mi

151 , the impact of vitamin B12 availability and methotrexate exposure on Daphnia magna, which we hypothe

152 Etanercept-methotrexate first versus triple therapy first.

153 phamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine

154 mab for induction or maintenance therapy, or methotrexate for induction therapy.

155 ase the risk of a second NMSC when used with methotrexate for RA.

156 recorded in three (3%) patients who received methotrexate for the full 52 week treatment period.

157 igh-dose methotrexate is superior to Capizzi methotrexate for the treatment of high-risk B-acute lymp

158 ectiveness of Adalimumab in combination with MethOtRExate for the treatment of juvenile idiopathic ar

159 tinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis i

160 compared with 12 (32%) of 37 patients in the methotrexate group (p=0.027).

161 ab 0.8 mg/kg group and 15 (41%) of 37 in the methotrexate group achieved clear or minimal PGA (p=0.08

162 ent, occurring in 14 patients (13.0%) in the methotrexate group and 8 patients (7.4%) in the mycophen

163 ry end point occurred in 170 patients in the methotrexate group and in 167 in the placebo group (inci

164 ry end point occurred in 201 patients in the methotrexate group and in 207 in the placebo group (inci

165 nse was achieved in 37 (41%) patients in the methotrexate group compared with three (10%) patients in

166 eatment success occurred in 6 (33.3%) in the methotrexate group vs 14 (63.6%) in the mycophenolate gr

167 nt success was achieved in 58 (74.4%) in the methotrexate group vs 42 (55.3%) in the mycophenolate gr

168 ccess occurred in 64 (66.7%) patients in the methotrexate group vs 56 (57.1%) in the mycophenolate gr

169 mumab 0.4 mg/kg group; 21 [57%] of 37 in the methotrexate group).

170 216 patients (95% CI 35-48) in the continued methotrexate group, 147 (68%) of 217 patients (62-74) re

171 (19%) of 216 (95% CI 14-25) in the continued methotrexate group, 97 (45%) of 217 (38-51) receiving up

172 weeks (methotrexate-methotrexate vs placebo-methotrexate groups).

173 Interestingly, methotrexate has been identified as a JAK/STAT inhibitor

174 However, methotrexate has limited clinical and cost effectiveness

175 (560 or 840 mg daily dosing) with high-dose methotrexate (HD-MTX) and rituximab in patients with CNS

176 y diagnosed patients after in vivo high-dose methotrexate (HDMTX) (1 g/m2) treatment, defined ALL sub

177 h intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine would impro

178 g prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial.

179 determining the transport of paclitaxel and methotrexate in brain tumour.

180 iple therapy to be noninferior to etanercept-methotrexate in patients with active rheumatoid arthriti

181 witching from methotrexate versus continuing methotrexate in patients with inadequate response to met

182 intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-

183 52 week risk-benefit profile of subcutaneous methotrexate in patients with psoriasis.

184 52 week risk-benefit profile of subcutaneous methotrexate in patients with psoriasis.

185 al and functional outcomes versus continuing methotrexate in this methotrexate inadequate-responder p

186 s in patients with an inadequate response to methotrexate in this trial.

187 comes versus continuing methotrexate in this methotrexate inadequate-responder population.

188 ntribute to the anti-inflammatory actions of methotrexate, including the inhibition of purine and pyr

189 Methotrexate-induced AMPK activation leads to decreased

190 6 or 7 times per week protected more against methotrexate-induced gastrointestinal AEs than did weekl

191 Methotrexate inhibited the catalytic activity of MNADK i

192 chemotherapy without serial intraventricular methotrexate injection failed to achieve the targeted 2-

193 DK in hepatocytes and in livers in mice with methotrexate injection.

194 plemented with 0.5% sodium cholate) or given methotrexate intraperitoneally.

195 100 mg/m(2) orally on days 1-14; 40 mg/m(2) methotrexate intravenously on days 1 and 8; and 600 mg/m

196 Methotrexate is generally the first-line drug for the tr

197 Although methotrexate is one of the first examples of intelligent

198 Methotrexate is one of the most commonly used systemic d

199 High-dose methotrexate is superior to Capizzi methotrexate for the

200 ed dosing schedule should be considered when methotrexate is used in this patient group.

201 ree survival (DFS) compared with intrathecal methotrexate (IT MTX), when given on a modified augmente

202 Low-dose methotrexate (LD-MTX) is the most commonly used drug for

203 he safety and potential efficacy of low-dose methotrexate (LDMTX) in treated HIV.

204 Systemic chemotherapy and intraventricular methotrexate led to favorable survival in both iSHH subt

205 er postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide

206 armacokinetic analysis showed that high-dose methotrexate maximum plasma concentration (estimate = 0;

207 te treatment of all patients up to 52 weeks (methotrexate-methotrexate vs placebo-methotrexate groups

208 Methotrexate might be used in patients who relapse.

209 ach to inflammation inhibition with low-dose methotrexate might provide similar benefit.

210 This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategi

211 f the therapeutically relevant drug molecule methotrexate (MTX) and its metabolites 7-hydroxy methotr

212 Methotrexate (MTX) and pemetrexed (PTX) are two examples

213 Several methotrexate (MTX) based treatments (free MTX, MTX loade

214 hand, pharmacological inhibition of DHFR by methotrexate (MTX) causes severe defects in oligodendroc

215 irment (CRCI), we recently demonstrated that methotrexate (MTX) chemotherapy induces complex glial dy

216 t is observed a decrease in immune response, methotrexate (MTX) was used only to compare the PnV effe

217 avenous immunoglobulins (IVIG), mepolizumab, methotrexate (MTX), omalizumab, upadacitinib and ustekin

218 we found five of these compounds, including methotrexate (MTX), promoted P23H rhodopsin degradation

219 The polyarginine moiety of affibody sealed methotrexate (MTX)-loaded MUA-Au NCs through charge effe

220 mg/kg (n=38), adalimumab 0.4 mg/kg (n=39) or methotrexate (n=37).

221 we randomly assigned 120 patients to receive methotrexate (n=91) or placebo (n=29).

222 ular Inflammation Reduction Trial), low-dose methotrexate neither reduced IL-1beta, IL-6, or high-sen

223 These data highlight a reciprocal effect of methotrexate on anabolic and catabolic processes and imp

224 aches, we investigated the global effects of methotrexate on cellular metabolism.

225 every other week starting at week 1, or oral methotrexate once weekly (0.1-0.4 mg/kg) for 16 weeks.

226 ared with non-biologic systemic therapies or methotrexate-only (etanercept: HR = 1.47, 95% CI = 0.95-

227 tuximab vedotin versus physician's choice of methotrexate or bexarotene.

228 prophylaxis (cyclosporine or tacrolimus plus methotrexate or mycophenolate) or standard GVHD prophyla

229 idence comparing biologics with one another, methotrexate, or placebo.

230 py, oral tofacitinib (5 mg twice daily) plus methotrexate, or subcutaneous adalimumab (40 mg every ot

231 el immunotherapy agents (P = .028), low-dose methotrexate (P < .0001), and chemotherapy (P < .0001).

232 xate, and 1.86, 1.48-2.32 for tocilizumab vs methotrexate, p<0.0001 for both comparisons).

233 multi-agent chemotherapy with Capizzi-based methotrexate/pegaspargase (C-MTX) in patients with newly

234 per day, celecoxib 200 mg twice per day, and methotrexate per week.

235 with four intensification courses (high-dose methotrexate plus L-asparaginase and hyper-CVAD plus ofa

236 ctivity, leading to significant reduction in methotrexate polyglutamation, and therefore likely contr

237 arthritis who was taking glucocorticoids and methotrexate presented to the emergency department in De

238 previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or

239 8.1%) reported 1 or more AEs associated with methotrexate, primarily gastrointestinal (67 [24.8%]).

240 of 523 patients who received adalimumab plus methotrexate reported treatment-emergent adverse events.

241 MPK activation as a metabolic determinant of methotrexate response.

242 Adalimumab in combination with methotrexate resulted in additional costs of pound 39 31

243 Methotrexate results in persistent activation of microgl

244 erpatient differences in the accumulation of methotrexate's active polyglutamylated metabolites (MTXP

245 riasis to aid in determining eligibility for methotrexate sodium (MTX) therapy, monitor for the devel

246 Methotrexate sodium (OR, 0.60; 95% CI, 0.29-1.22), merca

247 In mice given injections of methotrexate, supplementation of a diet with nicotinamid

248 tacrolimus/sirolimus (Tac/Sir) vs tacrolimus/methotrexate (Tac/Mtx) as graft-versus-host disease (GVH

249 lation (thiopurine-allopurinol, biologicals, methotrexate, tacrolimus) and were subsequently treated

250 ontinuation of the drug was more likely with methotrexate than tumor necrosis factor inhibitors, but

251 a ratiometric fluorescent sensor protein for methotrexate that exhibits large dynamic ranges both in

252 With the exception of methotrexate, the use of medications for IBD should not

253 nts with active rheumatoid arthritis despite methotrexate therapy are lacking.

254 er forms of inflammatory arthritis, low-dose methotrexate therapy remains the gold standard in RA the

255 der with active rheumatoid arthritis despite methotrexate therapy.

256 patients with psoriasis receiving long-term methotrexate therapy.

257 with active RA despite at least 12 weeks of methotrexate therapy.

258 Combination immunomodulator (thiopurine or methotrexate) therapy mitigated the risk of developing a

259 s reported by one (<1%) patient on continued methotrexate, three (1%) on upadacitinib 15 mg, and six

260 Methotrexate-treated cancer survivors had significantly

261 to 22.5 mg/week was allowed after 8 weeks of methotrexate treatment if patients had not achieved at l

262 We show that methotrexate treatment increases the intracellular conce

263 placebo for the first 16 weeks, followed by methotrexate treatment of all patients up to 52 weeks (m

264 dition of SAM during methionine depletion or methotrexate treatment was sufficient to rescue endolyso

265 rrently moderate to severe disease, and were methotrexate treatment-naive.

266 h reduced AMPK activity are less affected by methotrexate treatment.

267 These effects were comparable with the Methotrexate treatment.

268 Three malignancies (one [<1%] on continued methotrexate, two [1%] on upadacitinib 15 mg), three adj

269 eitis) trial (identifier, ISRCTN10065623) of methotrexate (up to 25 mg weekly) with or without fortni

270 iple glutamate residues (polyglutamation) to methotrexate upon their entry into the cells.

271 receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to

272 inferiority was declared for tofacitinib and methotrexate versus adalimumab and methotrexate (differe

273 padacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients

274 termine the cost-effectiveness of etanercept-methotrexate versus triple therapy as a first-line strat

275 ved one complete or two incomplete cycles of methotrexate-vinblastane.

276 n the pazopanib group and 20 patients in the methotrexate-vinblastine group were assessable for activ

277 10, 21%) and diarrhoea (n=7, 15%) and in the methotrexate-vinblastine group were neutropenia (n=10, 4

278 ed (n=48 in the pazopanib group; n=24 in the methotrexate-vinblastine group).

279 group, as did and six patients (27%) in the methotrexate-vinblastine group.

280 eatments are approved for this disease, with methotrexate-vinblastine the only chemotherapy regimen a

281 The proportion of patients treated with methotrexate-vinblastine who had not progressed at 6 mon

282 5% CI 1.00-1.29, p=0.06 for tocilizumab plus methotrexate vs methotrexate, 1.14, 1.01-1.29, p=0.0356

283 2.00, 95% CI 1.59-2.51 for tocilizumab plus methotrexate vs methotrexate, and 1.86, 1.48-2.32 for to

284 ethotrexate, and p=0.59 for tocilizumab plus methotrexate vs tocilizumab).

285 Methotrexate was administered as a 15 mg/m(2) intravenou

286 Higher plasma methotrexate was also associated with higher functional

287 Methotrexate was associated with elevations in liver-enz

288 A higher plasma concentration of methotrexate was associated with executive dysfunction a

289 The OBD of methotrexate was determined on the basis of the clinical

290 Subcutaneous methotrexate was generally well tolerated; no patients d

291 nts were recruited in phase I, and 9 mg/m(2) methotrexate was identified as the OBD.

292 nt with prednisone and either ciclosporin or methotrexate was more effective than prednisone alone.

293 Methotrexate was used by 270 patients (69.2%), biologic

294 s of Ashwashila (ASHW) and standard of care, Methotrexate were given to the CAIA animals for two week

295 h active rheumatoid arthritis despite stable methotrexate were randomly assigned 2:2:1:1 to switch to

296 Patients who were taking a stable dose of methotrexate were randomly assigned in a 2:1 ratio to re

297 from week 14, patients assigned to continue methotrexate were switched to 15 mg or 30 mg once-daily

298 to potentiate the antiparasitic activity of methotrexate when evaluated in combination against T. br

299 identify the optimal biologic dose (OBD) of methotrexate when given along with erlotinib and celecox

300 Anti-TNF treatment, as well as metformin and methotrexate, which are associated with decreased stroke

301 erapy comprising cisplatin, doxorubicin, and methotrexate with intercalated surgery is the standard o

302 Conversely, the combination of methotrexate with the AMPK activator, phenformin, potent

303 nalysis suggested that first-line etanercept-methotrexate would result in 0.15 additional lifetime QA